Tatva Chintan Pharma Chem: Promoter Declaration on Non-Encumbrance of Shares for FY26
Tatva Chintan Pharma Chem announced on 19 May 2026, that the promoter group, including Ajay Mansukhlal Patel, declared no encumbrance of shares for the financial year ended 31 March 2026. The declaration complies with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The announcement is a routine compliance disclosure and does not have a significant impact on the company's operations or stock price.
The announcement is a regulatory disclosure regarding the non-encumbrance of shares, which is neither inherently positive nor negative.
Tatva Chintan Pharma Chem Limited has announced that the promoter, along with persons acting in concert, have declared that they have not made any encumbrance of shares of the company, directly or indirectly, during the financial year ended on 31 March 2026. This declaration is made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The announcement was made on 19 May 2026, with the declaration dated 01 April 2026.
The promoter, Ajay Mansukhlal Patel (DIN: 00183745), has made the declaration on behalf of himself and other members of the promoter group. The promoter group includes Priti Ajay Patel, Dharmeshkumar Mansukhlal Patel, Ishani Ajay Patel, Kabir Ajay Patel, Preyash Yashvantlal Potla, Raxaben Mansukhlal Patel, Simabahen Tejaskumar Rangrej, Ushaben Potla, Yashvantlal Ramanlal Potla, and Star Enterprise.
A copy of the declaration has also been sent to the Chairman of the Audit Committee of the Board of Directors of Tatva Chintan Pharma Chem Limited.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.